tetano
Editor, Senior Moderator
Fr
ont Immunol
. 2023 Sep 6;14:1244373.
doi: 10.3389/fimmu.2023.1244373. eCollection 2023. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study
Nani Xu[SUP] 1 [/SUP], Yu Xu[SUP] 2 [/SUP], Rongrong Dai[SUP] 3 [/SUP], Lin Zheng[SUP] 1 [/SUP], Pan Qin[SUP] 1 [/SUP], Peng Wan[SUP] 2 [/SUP], Yejing Yang[SUP] 1 [/SUP], Jianmin Jiang[SUP] 4 5 [/SUP], Hangjie Zhang[SUP] 4 5 [/SUP], Xiaowei Hu[SUP] 1 [/SUP], Huakun Lv[SUP] 4 5 [/SUP]
Affiliations
Introduction: China experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.
Methods: We conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
Results: A total of 191 participants aged ≥18 years who had completed a three-dose regimen of the inactivated SARS-CoV-2 vaccine 6 months earlier were recruited to receive the intramuscular Ad5-nCoV booster or the inactivated SARS-CoV-2 vaccine. The Ad5-nCoV group had significantly higher antibody levels compared with the inactivated vaccine group at 6 months after the fourth vaccination dose. After the pandemic, the breakthrough infection rate for the Ad5-nCoV and the inactivated vaccine groups was 77.89% and 78.13%, respectively. Survival curve analysis (p = 0.872) and multivariable logistic regression analysis (p = 0.956) showed no statistically significant differences in breakthrough infection between the two groups.
Discussion: Compared with a homologous fourth dose, a heterologous fourth dose of Ad5-nCoV elicited a higher immunogenic response in healthy adults who had been immunized with three doses of inactivated vaccine. Nevertheless, the efficacy of the two vaccine types was equivalent after the pandemic.
Keywords: Ad5-nCoV; COVID-19; SARS-CoV-2; breakthrough infection; fourth dose.
ont Immunol
. 2023 Sep 6;14:1244373.
doi: 10.3389/fimmu.2023.1244373. eCollection 2023. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study
Nani Xu[SUP] 1 [/SUP], Yu Xu[SUP] 2 [/SUP], Rongrong Dai[SUP] 3 [/SUP], Lin Zheng[SUP] 1 [/SUP], Pan Qin[SUP] 1 [/SUP], Peng Wan[SUP] 2 [/SUP], Yejing Yang[SUP] 1 [/SUP], Jianmin Jiang[SUP] 4 5 [/SUP], Hangjie Zhang[SUP] 4 5 [/SUP], Xiaowei Hu[SUP] 1 [/SUP], Huakun Lv[SUP] 4 5 [/SUP]
Affiliations
- PMID: 37736100
- PMCID: PMC10510200
- DOI: 10.3389/fimmu.2023.1244373
Introduction: China experienced a record surge of coronavirus disease 2019 cases in December 2022, during the pandemic.
Methods: We conducted a randomized, parallel-controlled prospective cohort study to evaluate efficacy and antibody duration after a fourth-dose booster with Ad5-nCoV or inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
Results: A total of 191 participants aged ≥18 years who had completed a three-dose regimen of the inactivated SARS-CoV-2 vaccine 6 months earlier were recruited to receive the intramuscular Ad5-nCoV booster or the inactivated SARS-CoV-2 vaccine. The Ad5-nCoV group had significantly higher antibody levels compared with the inactivated vaccine group at 6 months after the fourth vaccination dose. After the pandemic, the breakthrough infection rate for the Ad5-nCoV and the inactivated vaccine groups was 77.89% and 78.13%, respectively. Survival curve analysis (p = 0.872) and multivariable logistic regression analysis (p = 0.956) showed no statistically significant differences in breakthrough infection between the two groups.
Discussion: Compared with a homologous fourth dose, a heterologous fourth dose of Ad5-nCoV elicited a higher immunogenic response in healthy adults who had been immunized with three doses of inactivated vaccine. Nevertheless, the efficacy of the two vaccine types was equivalent after the pandemic.
Keywords: Ad5-nCoV; COVID-19; SARS-CoV-2; breakthrough infection; fourth dose.